Thomas Moritz

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections

Philipp Schütt, Dieter Brandhorst, Werner Stellberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2006 · 124 citations

Clinical Immunology, Immunology, Immune System +17

Combination therapy with interferon alpha‐2b plus low‐dose interferon gamma in pretreated patients with Ph‐positive chronic myelogenous leukaemia

Ursula Wandl, O. Kloke, M. Nagel‐Hiemke et al. · British Journal of Haematology · 1992 · 33 citations

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival

Philipp Schütt, Peter R. Ebeling, Ulrike Buttkereit et al. · Annals of Hematology · 2005 · 31 citations

Inflammation, Hematological Malignancy, Medicine +9

Effect of DNase on the activity of neutrophil elastase, cathepsin G and proteinase 3 in the presence of DNA

Jérôme Duranton, Didier Belorgey, Jacqueline Carrère et al. · FEBS Letters · 2000 · 31 citations

The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients

Philipp Schütt, Vera Rebmann, Dieter Brandhorst et al. · Human Immunology · 2008 · 17 citations

Hematological Malignancy, Autoimmune Disease, Mixed-phenotype Acute Leukemia +12